COMMUNIQUÉS West-GlobeNewswire

Sanofi et la DNDi soumettent une demande d'approbation de leur traitement contre la maladie du sommeil à l'Agence européenne des médicaments
31/01/2018
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi et la DND i soumettent leur traitement contre la maladie du sommeil à l'évaluation de l'Agence européenne des médicaments Le féxinidazole serait le [...]
Change in the Number of Shares and Votes in Immunicum
31/01/2018
Press Release 31 January 2018 Change in the Number of Shares and Votes in Immunicum Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid [...]
ESPERITE (ESP) : L1 Capital subscribes to the 14th tranche of investment today
31/01/2018
Amsterdam, The Netherlands - 31 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 14 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
INNATE PHARMA : Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory Board
31/01/2018
Prof. Jean-Yves Blay appointed to the Innate Pharma Supervisory Board Marseille, France, January 31, 2018, 7:00 AM CET Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that Prof. [...]
INNATE PHARMA : Le Professeur Blay nommé au Conseil de surveillance d'Innate Pharma
31/01/2018
LE PROFESSEUR BLAY NOMMÉ AU CONSEIL DE SURVEILLANCE D'INNATE PHARMA Marseille, le 31 janvier 2018, 7h00 CET Innate Pharma SA (la « Société » - Euronext Paris : FR0010331421 - IPH) annonce aujourd'hui la nomination du [...]
ASLAN Pharmaceuticals Sponsors Cholangiocarcinoma Foundation Annual Conference 2018
31/01/2018
SINGAPORE, Jan. 31, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN) (6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the [...]
Arcturus Therapeutics Announces Extraordinary General Meeting of Shareholders
31/01/2018
SAN DIEGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd., or Arcturus (NASDAQ: ARCT ), an RNA medicines company, today announced that it will hold an extraordinary general meeting of shareholders on [...]
Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region
31/01/2018
DUBLIN and SHANGHAI - January 30, 2018 - Medtronic plc (NYSE: MDT ) today announced that Alex Gu, previously Vice President, Regional Growth Initiatives, Greater China, and leader of Medtronic's Minimally Invasive [...]
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California
31/01/2018
LA JOLLA, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
National Research Corporation to Broadcast its 2017 Fourth Quarter and Year-End Conference Call Live on the Internet
30/01/2018
Lincoln, Nebraska, Jan. 30, 2018 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ: NRCIA ) (NASDAQ: NRCIB ) today announced that it will provide an online web simulcast of its 2017 fourth quarter and year-end [...]
Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals
30/01/2018
VANCOUVER, British Columbia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN ), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare [...]
Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States
30/01/2018
HOUSTON, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Avinger Announces Reverse Stock Split
30/01/2018
REDWOOD CITY, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ: AVGR ), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will effect a 1- [...]
Vistin Pharma ASA : Vistin Pharma to postpone the expansion of the metformin production capacity
30/01/2018
Oslo, Norway, 30 January 2018 Norwegian pharmaceutical company Vistin Pharma ASA announced today that it has decided to postpone the construction of the new NOK 120 million production line at the Company's dedicated [...]
Vical Announces Restructuring to Focus Resources on HSV-2 and Antifungal Clinical Programs
30/01/2018
SAN DIEGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq: VICL ) today announced a restructuring to conserve capital and to focus its efforts on VL-2397, its antifungal drug product candidate which is [...]
Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option
30/01/2018
CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB ) (the “Company” or “SLDB”), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, [...]
Advanced Biomedical Technologies Inc. Granted New Patent Strengthening its Core Technology
30/01/2018
SHENZHEN, CHINA and NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Advanced Biomedical Technologies Inc. (OTCQB:ABMT), a developer and manufacturer of orthopaedic internal fixation devices, today announced the State [...]
AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
30/01/2018
CHICAGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ: AVXS ), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, [...]
resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
30/01/2018
BOSTON, Jan. 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (NASDAQ: TORC ), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging- [...]

Pages